Experimental brain cancer cocktail shows promise in early trial
NCT ID NCT05734560
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental immunotherapy drugs, D2C7-IT and 2141-V11, in adults with a newly diagnosed, aggressive type of brain cancer called glioblastoma. The drugs are given directly into the brain after surgery, followed by injections near the neck lymph nodes. The goal is to see if this combination is safe and helps patients live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- D2C7-IT and 2141-V11 (immunotherapy drugs)
- What this could lead to
- If successful, this could lead to a new treatment option that extends survival for people with a hard-to-treat brain cancer.
- What could go wrong
- This is an early-phase trial with only 50 participants, so results may not apply to everyone. The drugs are experimental and could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.